Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Lupus Erythematosus

New Insights into CD8+ T Cells & Lupus

Lara C. Pullen, PhD  |  July 6, 2021

A recent study demonstrated that exposure to type I interferon contributes to the pathogenesis of SLE via the metabolic rewiring of CD8+ T cells, which promotes cell death.

Platelets: An Underrecognized Piece of the Lupus Puzzle

Lara C. Pullen, PhD  |  June 14, 2021

Platelets may be a key source of mitochondrial antigens in systemic lupus erythematosus, according to a recent study.

Lupus or Not? Machine Learning May Help Diagnose Lupus Early

Lara C. Pullen, PhD  |  May 19, 2021

Can machine learning aid clinicians in diagnosing systemic lupus erythematosus? Adamichou et al. designed an algorithm that uses classical features of lupus to simulate medical reasoning and identify lupus early in the disease process. They were able to validate the algorithm, which demonstrated high sensitivity, specificity and accuracy.

A 2021 Update on Lupus Management & Treatment

Jason Liebowitz, MD, FACR  |  May 13, 2021

At the 2021 ACR State-of-the-Art Clinical Symposium, Saira Sheikh, MD, associate pro­fessor of Medicine and director of the Rheumatology Lupus Clinic, University of North Carolina, Chapel Hill, provided an update on the past, present and future of the management of systemic lupus erythematosus (SLE). This year, hydroxychloroquine received a great deal of attention, given early…

Andrey_Popov / shutterstock.com

Case Study: The Importance of Understanding the Patient’s Perspective

Manuel F. Ugarte-Gil, MD, MSc, & Graciela S. Alarcón, MD, MPH  |  May 13, 2021

A 26-year-old Peruvian woman presented to the emergency department of a large teaching hospital in Lima, Peru, with epistaxis and hematomas that had occurred over the preceding few days; she was found to have severe thrombocytopenia and a normocytic, normochromic anemia. She was treated with pulse doses of methylprednisolone; however, within two days, she presented…

Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund Established

From the College  |  April 17, 2021

The Lupus and Allied Diseases Association Inc. established the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund at the Rheumatology Research Foundation, effective March 1. This fund was established to honor the life and legacy of Marc Chevrier, MD, PhD, FACR, a pioneer and patient advocate in the field of lupus. About Dr….

Stock Footage Inc / shutterstock.com

ACR, Ophthalmologists & Dermatologists Issue Joint Hydroxychloroquine Statement

Ruth Jessen Hickman, MD  |  April 17, 2021

Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…

FDA Approves Belimumab & Voclosporin for Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  March 24, 2021

In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.

Improving Demographic Representation & Equity in Rheumatology Research

Allison Plitman  |  March 18, 2021

A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.

Autoantibodies Against LINE-1 p40 May Be More Common in Patients with Active SLE

Vanessa Caceres  |  March 17, 2021

Researchers found nearly all systemic lupus erythematosus (SLE) patients have autoantibodies against long interspersed nuclear elements (LINE-1) p40. These findings suggest LINE-1 may be involved in the pathogenesis of SLE.

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences